Enter your details to join our mobile app waitlist and receive early access to the Bell Direct App.
In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.
In this video, Dr. Lipscombe covers:
· (0:47): An overview of PIQ and its FY26 goals
· (1:38): The significance of three world-first blood tests
· (5:26): The global addressable markets for these conditions
· (6:25): Clinical trial progress and commercialisation roadmap
· (8:14): How the diagnostic tests work and deliver value to patients
· (9:16): Commercialisation strategy across key regions
· (11:23): Additional assets in the PIQ pipeline
· (12:36): What investors can expect over the next 12 months
Note: This interview was recorded on 3 July 2025.